918 related articles for article (PubMed ID: 12117079)
21. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease.
Ritchie CW; Ames D; Clayton T; Lai R
Am J Geriatr Psychiatry; 2004; 12(4):358-69. PubMed ID: 15249273
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
Burns A; Spiegel R; Quarg P
Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039
[TBL] [Abstract][Full Text] [Related]
23. Rivastigmine for Alzheimer's disease.
Birks JS; Grimley Evans J
Cochrane Database Syst Rev; 2015 Apr; (4):CD001191. PubMed ID: 25858345
[TBL] [Abstract][Full Text] [Related]
24. Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors.
Nobili F; Koulibaly M; Vitali P; Migneco O; Mariani G; Ebmeier K; Pupi A; Robert PH; Rodriguez G; Darcourt J
J Nucl Med; 2002 Aug; 43(8):983-90. PubMed ID: 12163621
[TBL] [Abstract][Full Text] [Related]
25. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Robert P
Curr Med Res Opin; 2002; 18(3):156-71. PubMed ID: 12094826
[TBL] [Abstract][Full Text] [Related]
26. Treatment of Alzheimer's disease in the long-term-care setting.
Smith DA
Am J Health Syst Pharm; 2009 May; 66(10):899-907. PubMed ID: 19420308
[TBL] [Abstract][Full Text] [Related]
27. A multinational, randomised, 12-week, comparative study of donepezil and rivastigmine in patients with mild to moderate Alzheimer's disease.
Wilkinson DG; Passmore AP; Bullock R; Hopker SW; Smith R; Potocnik FC; Maud CM; Engelbrecht I; Hock C; Ieni JR; Bahra RS
Int J Clin Pract; 2002; 56(6):441-6. PubMed ID: 12166542
[TBL] [Abstract][Full Text] [Related]
28. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.
Marin D; Amaya K; Casciano R; Puder KL; Casciano J; Chang S; Snyder EH; Cheng I; Cuccia AJ
Int Psychogeriatr; 2003 Dec; 15(4):385-98. PubMed ID: 15000418
[TBL] [Abstract][Full Text] [Related]
29. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
Aguglia E; Onor ML; Saina M; Maso E
Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
[TBL] [Abstract][Full Text] [Related]
30. Donepezil for dementia due to Alzheimer's disease.
Birks J; Harvey RJ
Cochrane Database Syst Rev; 2006 Jan; (1):CD001190. PubMed ID: 16437430
[TBL] [Abstract][Full Text] [Related]
31. Defining treatment response to donepezil in Alzheimer's disease: responder analysis of patient-level data from randomized, placebo-controlled studies.
Burns A; Yeates A; Akintade L; Del Valle M; Zhang RY; Schwam EM; Perdomo CA
Drugs Aging; 2008; 25(8):707-14. PubMed ID: 18665662
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Mossello E; Tonon E; Caleri V; Tilli S; Cantini C; Cavallini MC; Bencini F; Mecacci R; Marini M; Bardelli F; Sarcone E; Razzi E; Biagini CA; Masotti G
Arch Gerontol Geriatr Suppl; 2004; (9):297-307. PubMed ID: 15207427
[TBL] [Abstract][Full Text] [Related]
33. The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
Kobayashi H; Ohnishi T; Nakagawa R; Yoshizawa K
Int J Geriatr Psychiatry; 2016 Aug; 31(8):892-904. PubMed ID: 26680338
[TBL] [Abstract][Full Text] [Related]
34. Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.
Rolinski M; Fox C; Maidment I; McShane R
Cochrane Database Syst Rev; 2012 Mar; 2012(3):CD006504. PubMed ID: 22419314
[TBL] [Abstract][Full Text] [Related]
35. [A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia].
Schreiter Gasser U; Gasser T
Fortschr Med Orig; 2001 Nov; 119(3-4):135-8. PubMed ID: 11789125
[TBL] [Abstract][Full Text] [Related]
36. Rivastigmine for Alzheimer's disease.
Birks J; Iakovidou V; Tsolaki M
Cochrane Database Syst Rev; 2000; (2):CD001191. PubMed ID: 10796621
[TBL] [Abstract][Full Text] [Related]
37. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial.
Courtney C; Farrell D; Gray R; Hills R; Lynch L; Sellwood E; Edwards S; Hardyman W; Raftery J; Crome P; Lendon C; Shaw H; Bentham P;
Lancet; 2004 Jun; 363(9427):2105-15. PubMed ID: 15220031
[TBL] [Abstract][Full Text] [Related]
38. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
39. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
Kaduszkiewicz H; Zimmermann T; Beck-Bornholdt HP; van den Bussche H
BMJ; 2005 Aug; 331(7512):321-7. PubMed ID: 16081444
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
